What should a supplement brand check on its label and marketing claims before launch?

A pre-launch review covers three layers: the physical label FDA regulates, the wider labeling that travels with the product, and the advertising the FTC regulates. Every statement in all three must be accurate, allowed for a dietary supplement, and backed by evidence you already hold on the day you launch.

Founders often treat the label as a design file and the claims as a copy file. Regulators do not. FDA looks at the label, inserts and, in practice, the web pages that sell the product. The FTC looks at anything that persuades a buyer, including ads, emails, influencer posts and marketplace listings. A claim that is fine on the bottle can still be a problem in a video where a founder adds a word or two.

The cleanest way to run the review is to list every surface before you write a single claim:

• Package: principal display panel, information panel, any carton and any insert.
• Owned media: product page, landing pages, FAQ, blog posts that link to the product, email and SMS templates.
• Paid and partner media: ad copy, creator briefs, affiliate pages, retailer and marketplace listings.
• Sales tools: retailer sell sheets and trade-show material.

Then run each surface through the same checklist below. Our wider overview of FTC and FDA rules for supplement advertising explains how the two agencies split the work.

Put every sentence into one bucket: structure/function claim, nutrient content claim, health claim, or disease claim. Structure/function claims need the disclaimer and FDA notification. Nutrient content and health claims must meet FDA definitions or authorizations. Disease claims are not allowed for a supplement at all.

A structure/function claim describes how a nutrient or ingredient affects normal structure or function, such as "supports healthy digestion." A disease claim says or implies the product diagnoses, treats, cures, mitigates or prevents disease. FDA's criteria in 21 CFR 101.93(g) are wider than most marketers expect. A statement can be a disease claim if it targets the signs or symptoms of a disease, positions the product as a substitute for a drug, or says it augments a therapy.

Implied claims are claims

The rule lists ways a claim can be implied without disease words. These include the product name, a formulation statement about an ingredient known as a drug, a citation to a publication about a disease use, use of the word "disease," and pictures, vignettes or symbols. A heart-shaped graphic next to an ECG trace can do the work a sentence would have done.

Nutrient content claims such as "high in," "good source of" or "low" have defined thresholds under FDA rules, so check the numbers on the panel against them. Authorized health claims are a separate, narrow category. Treat them as a counsel question rather than a copywriting choice.

Build one substantiation file per claim before the label goes to print. The FTC expects competent and reliable scientific evidence, generally randomized controlled human trials for health benefit claims. The studies should match your dose, formulation, population and the exact benefit stated. Ingredient safety and manufacturing claims need their own records.

The FTC guidance, which replaced its 1998 supplement advertising guide in December 2022, sets the bar. It asks whether studies had a control group and blinding, whether results were statistically significant and clinically meaningful, and whether the whole body of research points the same way. Animal and test-tube work does not carry a human benefit claim on its own. FDA has its own nonbinding guidance on substantiating structure/function claims, issued in 2009, which points the same way.

What goes in each claim file

• The exact claim wording and every surface it appears on.
• The studies relied on, with a note on how dose, form and population compare to your product.
• Studies that cut against the claim, and why the totality still supports it.
• A reviewer sign-off with date and version.

Ingredient and quality checks

• New dietary ingredients. An ingredient not marketed in the US before October 15, 1994 may need a premarket notification to FDA at least 75 days before launch under 21 CFR 190.6. Confirm status with your supplier and counsel.
• "GMP" or quality wording. Supplement makers must follow FDA's cGMP rule in 21 CFR Part 111. Wording that implies FDA approval or certification of your facility is a problem, because FDA does not approve supplements before sale.
• "Made in USA." Under 16 CFR Part 323, an unqualified claim on a label requires final assembly or processing in the US, all significant processing in the US, and all or virtually all ingredients made and sourced in the US. Imported botanicals often mean a qualified claim instead. Our page on Made in USA and GMP claims covers the detail.

Sign-off should involve three people: the person who owns quality and formulation, the marketer who wrote the claims, and regulatory counsel who confirms the legal reading. Record each approval against a label version number. Re-run the review whenever the formula, a supplier, a claim or a sales channel changes.

Triggers for a fresh review

• A formula or dose change, even a small one.
• A new ingredient supplier, especially for imported botanicals.
• A new claim, a new study or a new market.
• A move into retail, a new marketplace, or a new ad platform.
• A new FDA or FTC rule, guidance or enforcement trend in your category.

Ichelon Consulting US is a marketing team, not a law firm. We do not give legal advice, and we always tell clients to confirm with counsel. What we do is build the claims matrix, write ad and listing copy that stays inside it, brief creators, and flag copy that drifts. Across ICG, we have worked only in healthcare since 2018. US retainers start from $499/month, custom-scoped. Goals are agreed each month and reported every Monday. See our supplement and D2C health brand marketing service, or book a call to walk through your label before it prints.